WuXi Biologics (Cayman) (WXXWY) Stock Price, News & Analysis

Company Overview

WuXi Biologics (Cayman) Inc., trading OTC as WXXWY, is a global contract research, development and manufacturing organization (CDMO) specializing in biologics. Founded as a spin-out from WuXi AppTec and incorporated in the Cayman Islands in 2017, the company offers end-to-end support across the biologics value chain. Its service portfolio encompasses discovery biology, analytical development, process chemistry and large-scale manufacturing for therapeutic proteins and antibodies.

The firm’s core offerings include the development of monoclonal antibodies, recombinant proteins and cell and gene therapy vectors. WuXi Biologics operates multiple cGMP facilities in China, the United States, Europe and Asia-Pacific, enabling seamless technology transfer and consistent production across geographies. Analytical and quality control services, such as bioassays, chromatography and biosafety testing, further underpin its integrated CDMO platform.

Since its Hong Kong Stock Exchange listing in June 2017, WuXi Biologics has expanded its global footprint through strategic capacity additions and partnerships with biopharmaceutical innovators. The company’s network includes manufacturing sites in Shanghai, Wuxi, Madison (Wisconsin), and European campuses in Germany and Ireland, as well as process development centers in Singapore and the U.S.

Under the leadership of Chairman and CEO Dr. Chris Chen, WuXi Biologics emphasizes innovation and technology transfer to accelerate biologics development. The management team comprises industry veterans with deep expertise in biologics R&D, regulatory affairs and large-scale manufacturing. Through its integrated platform, the company aims to streamline the path from candidate selection to commercial supply for its global clientele.

Key Stats

• Today's Range: $12.46 to $12.68
• 50-Day Range: $8.87 to $13.05
• 52-Week Range: $7.30 to $13.43
• Volume: 21,351 shs
• Average Volume: 57,155 shs
• Market Capitalization: $26.01 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

WuXi Biologics (Cayman) Stock Analysis - MarketRank™

WuXi Biologics (Cayman) scored higher than 41% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Hold

Consensus Rating

WuXi Biologics (Cayman) has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

WuXi Biologics (Cayman) has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 19.57%

Earnings Growth

Earnings for WuXi Biologics (Cayman) are expected to grow by 19.57% in the coming year, from $0.46 to $0.55 per share.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of WuXi Biologics (Cayman) has been sold short.

Short Interest Ratio / Days to Cover

WuXi Biologics (Cayman) has a short interest ratio ("days to cover") of 0.51, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in WuXi Biologics (Cayman) has recently decreased by 32.57%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

WuXi Biologics (Cayman) does not currently pay a dividend.

Dividend Growth

WuXi Biologics (Cayman) does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: N/A

News Sentiment

WuXi Biologics (Cayman) has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for WuXi Biologics (Cayman) this week, compared to 1 article on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, WuXi Biologics (Cayman) insiders have not sold or bought any company stock.

Percentage Held by Institutions

WuXi Biologics (Cayman) has minimal institutional ownership at this time.

Company Calendar

• Today: 9/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:WXXWY
• CIK: N/A
• Web: www.wuxibiologics.com.cn
• Phone: 8651081831205
• Fax: N/A
• Employees: 12,435
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 2,072,500,000
• Free Float: N/A
• Market Cap: $26.01 billion
• Optionable: Not Optionable
• Beta: N/A